Ocular Therapeutix, Inc. (OCUL)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1393434 · fiscal year ends in Dec
Closing price $7.30 on 29 Oct 2026; 52-week range $6.29 to $16.11.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $52.1M
- Revenue growth
- -8.1%
- Net income, last twelve months
- -$301.4M
- Earnings per share
- -$1.42
- Gross margin
- 87.1%
- Operating margin
- -603.0%
- Net margin
- -579.1%
- Free cash flow
- -$255.1M
- Return on equity
- -58.0%
- Market value
- $1.6B
- Cash
- $598.6M
- Debt
- $72.8M
- Debt to equity
- 0.14
- Shares outstanding
- 219.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $52.0M | -$270.0M | -$265.9M | -$1.42 | -$216.9M | 10-K filed 5 Feb 2026 |
| FY2024 | 31 Dec 2024 | $63.7M | -$171.8M | -$193.5M | -$1.22 | -$136.0M | 10-K filed 3 Mar 2025 |
| FY2023 | 31 Dec 2023 | $58.4M | -$82.4M | -$80.7M | -$1.02 | -$76.3M | 10-K filed 11 Mar 2024 |
| FY2022 | 31 Dec 2022 | $51.5M | -$78.7M | -$71.0M | -$0.97 | -$63.3M | 10-K filed 6 Mar 2023 |
| FY2021 | 31 Dec 2021 | $43.5M | -$78.0M | -$6.6M | -$0.98 | -$66.7M | 10-K filed 28 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $13.5M | -$78.8M | -$0.35 |
| Q1 FY2026 | 31 Mar 2026 | $10.8M | -$88.6M | -$0.40 |
| Q4 FY2025 | 31 Dec 2025 | $13.3M | -$64.7M | -$0.29 |
| Q3 FY2025 | 30 Sep 2025 | $14.5M | -$69.4M | -$0.38 |
| Q2 FY2025 | 30 Jun 2025 | $13.5M | -$67.8M | -$0.39 |
| Q1 FY2025 | 31 Mar 2025 | $10.7M | -$64.1M | -$0.38 |
| Q4 FY2024 | 31 Dec 2024 | $17.1M | -$48.4M | -$0.29 |
| Q3 FY2024 | 30 Sep 2024 | $15.4M | -$36.5M | -$0.22 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product revenue, net | $51.8M | 99.8% |
| Collaboration revenue | $128.0K | 0.2% |
Company events
The newest 8-K filings of 157 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 16 Oct 2026 | 8-K | Leadership change | 5.02 |
| 3 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 5 May 2026 | 8-K | Results | 2.02, 9.01 |
| 27 Feb 2026 | 8-K | Investor update | 7.01 |
| 5 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Jan 2026 | 8-K | Leadership change | 5.02 |
| 18 Dec 2025 | 8-K | Other events | 8.01 |
| 5 Dec 2025 | 8-K | Other events | 8.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 30 Sep 2025 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 30 Sep 2025 | 8-K | Other events | 8.01 |
Every filing
The newest filings with the SEC of 322 held.
| Filed | Form | Period |
|---|---|---|
| 16 Oct 2026 | 8-K | 14 Oct 2026 |
| 3 Aug 2026 | S-8 | – |
| 3 Aug 2026 | 10-Q | 30 Jun 2026 |
| 3 Aug 2026 | 8-K | 3 Aug 2026 |
| 12 Jun 2026 | 8-K | 10 Jun 2026 |
| 5 May 2026 | 10-Q | 31 Mar 2026 |
| 5 May 2026 | 8-K | 5 May 2026 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | DEF 14A | 11 Jun 2026 |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 27 Feb 2026 | 8-K | 27 Feb 2026 |
| 5 Feb 2026 | S-8 | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 8 Oct 2026 | Anderman Todd, Chief Legal Officer | Sale under a trading plan | 11,984 | $7.29 | $87.4K | 140,484 | 13 Oct 2026 |
| 2 Oct 2026 | Kaiser Peter, Chief Development Officer | Sale under a trading plan | 9,990 | $7.05 | $70.4K | 254,388 | 6 Oct 2026 |
| 2 Oct 2026 | Heier Jeffrey S., Chief Scientific Officer | Sale under a trading plan | 10,869 | $7.05 | $76.6K | 307,457 | 6 Oct 2026 |
| 31 Aug 2026 | Notman Donald, Chief Operating Officer | Sale outside a trading plan | 1,099 | $10.24 | $11.3K | 366,529 | 2 Sep 2026 |
| 24 Aug 2026 | Kaiser Peter, Chief Development Officer | Sale under a trading plan | 3,035 | $10.77 | $32.7K | 264,378 | 26 Aug 2026 |
| 24 Aug 2026 | Nayak Sanjay, Chief Strategy Officer | Sale under a trading plan | 1,897 | $10.78 | $20.4K | 326,898 | 26 Aug 2026 |
| 24 Aug 2026 | Heier Jeffrey S., Chief Scientific Officer | Sale under a trading plan | 3,296 | $10.78 | $35.5K | 318,326 | 26 Aug 2026 |
| 24 Aug 2026 | Dugel Pravin, See Remarks | Sale under a trading plan | 21,649 | $10.77 | $233.2K | 2,525,429 | 26 Aug 2026 |
| 3 Jun 2026 | Waheed Nadia, Chief Medical Officer | Sale under a trading plan | 14,828 | $8.27 | $122.6K | 300,079 | 5 Jun 2026 |
| 26 May 2026 | Dugel Pravin, See Remarks | Sale under a trading plan | 21,156 | $8.20 | $173.5K | 2,597,170 | 28 May 2026 |
| 26 May 2026 | Kaiser Peter, Chief Development Officer | Sale under a trading plan | 2,967 | $8.20 | $24.3K | 266,141 | 28 May 2026 |
| 26 May 2026 | Heier Jeffrey S., Chief Scientific Officer | Sale under a trading plan | 3,018 | $8.20 | $24.7K | 320,350 | 28 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 8 Oct 2026 | TODD ANDERMAN, Officer | 11,984 | $87.3K | 8 Oct 2026 |
| 2 Oct 2026 | PETER KAZUO KAISER, Officer | 9,990 | $70.5K | 2 Oct 2026 |
| 2 Oct 2026 | JEFFREY S. HEIER, Officer | 10,869 | $76.6K | 2 Oct 2026 |
| 31 Aug 2026 | DONALD D NOTMAN JR., Officer | 1,099 | $11.3K | 31 Aug 2026 |
| 24 Aug 2026 | SANJAY NAYAK, Officer | 1,897 | $20.5K | 24 Aug 2026 |
| 24 Aug 2026 | PETER KAZUO KAISER, Officer | 3,035 | $32.7K | 24 Aug 2026 |
| 24 Aug 2026 | JEFFREY S. HEIER, Officer | 3,296 | $35.5K | 24 Aug 2026 |
| 24 Aug 2026 | PRAVIN DUGEL, Officer | 21,649 | $233.2K | 24 Aug 2026 |
| 3 Jun 2026 | NADIA K. WAHEED, Officer | 14,828 | $122.6K | 3 Jun 2026 |
| 26 May 2026 | SANJAY NAYAK, Officer | 1,858 | $15.2K | 26 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Jul 2026 | BlackRock, Inc. | 13G amended | 7% | 15.2M |
| 15 May 2026 | Deep Track Capital, LP | 13G amended | 9.53% | 20.9M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G amended | 3.2% | 6.9M |
| 10 Feb 2026 | Deep Track Capital, LP | 13G | 5.13% | 11.2M |
| 10 Feb 2026 | Deep Track Capital, LP | 13G amended | 4.31% | 9.2M |
| 8 Dec 2025 | SUMMER ROAD LLC | 13G | 5.7% | 12.1M |
| 14 Nov 2025 | Venrock Healthcare Capital Partners III, L.P. | 13G amended | 7.3% | 12.9M |
| 14 Nov 2025 | Deep Track Capital, LP | 13G amended | 6.18% | 13.1M |
| 5 Nov 2025 | FMR LLC | 13G amended | 15% | 31.8M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 28.8M | -2.22% | 8.1 |
| 30 Sep 2026 | 29.4M | -1.74% | 7.25 |
| 15 Sep 2026 | 29.9M | +6.69% | 14.19 |
| 31 Aug 2026 | 28.1M | -1.61% | 8.96 |
| 14 Aug 2026 | 28.5M | +6.66% | 12.68 |
| 31 Jul 2026 | 26.7M | -1.08% | 13.49 |
| 15 Jul 2026 | 27.0M | +1.25% | 13.07 |
| 30 Jun 2026 | 26.7M | +0.9% | 6.56 |
Funds that hold it
From each fund's latest Form 13F.
300 funds held it at 30 Jun 2026: 135 added and 80 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 32,844,043 | $322.5M | +190,279 |
| Deep Track Capital, LP | 19,686,282 | $193.3M | 0 |
| BlackRock, Inc. | 19,376,555 | $190.3M | +3,243,624 |
| Avoro Capital Advisors LLC | 12,540,000 | $123.1M | +225,000 |
| Summer Road LLC | 12,208,296 | $119.9M | +328,471 |
| Venrock Adviser, LLC | 10,346,926 | $101.6M | 0 |
| Vanguard Capital Management LLC | 8,832,595 | $86.7M | +113,556 |
| Price T Rowe Associates Inc. | 7,623,533 | $74.9M | +1,726,384 |
| Logos Global Management LP | 5,300,000 | $52.0M | +1,450,000 |
| State Street Corp. | 5,233,282 | $51.4M | +524,863 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B